Home » Topics » Regulatory » NMPA

NMPA
RSS

China's State Food and Drug Administration approves first-in-human trial of APX-003

Nov. 13, 2012

ViroMed clear to conduct head-to-head phase III VM-501 study

April 2, 2012

Phase III trials of human fibrinogen to commence in China

March 28, 2012

Calcium channel blocker for hypertension clear to enter clinical testing in China

March 14, 2012

Antisense Therapeutics to form joint venture for development of ATL-1102

Feb. 29, 2012

Ready-to-use oral therapy approved in China for oral mucositis in patients with cancer

Feb. 28, 2012

Milestone developments for Novartis' Lucentis and Galvus in China

Jan. 19, 2012

F-647 approved in China

Sep. 22, 2011

First iguratimod product approved in China

Aug. 26, 2011

High-dose EPIAO approved in China to treat chemotherapy-associated anemia

July 14, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...